Skip to search formSkip to main contentSkip to account menu

LX1606

Known as: TPH Inhibitor LX1606, Tryptophan Hydroxylase Inhibitor LX1606 
National Institutes of Health

Related topics

Related topics

3 relations
LX1032telotristat etiprate

Broader (1)

telotristat

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Systemic therapeutic strategies for GEP-NETS: what can we expect in the future?
Over the last few years, there have been important advances in the understanding of the molecular biology of neuroendocrine… 
2012
2012
Relief of bowel-related symptoms with telotristat etiprate in octreotide refractory carcinoid syndrome: Preliminary results of a double-blind, placebo-controlled multicenter study.
312 Background: Diarrhea associated with carcinoid syndrome (CS) has been attributed to tumor production of serotonin… 
2012
2012
Relief of bowel-related symptoms with telotristat etiprate in octreotide refractory carcinoid syndrome: Preliminary results of a placebo-controlled, multicenter study.
312 Background: Diarrhea associated with carcinoid syndrome (CS) has been attributed to tumor production of serotonin… 
2012
2012
Mo2021 Lx1606 (Aka LX1032), a Peripheral Inhibitor of Serotonin Synthesis, Alleviates Development of Inflammatory Bowel Disease in a Preclinical Model
2011
2011
A phase II, multicenter, randomized, double-blind, placebo-controlled, ascending, multidose, U.S. study of oral LX1606 (aka LX1032) in patients with refractory symptomatic carcinoid syndrome.
TPS168 Background: Carcinoid tumors are associated with serotonin (5-HT) secretion. High levels of serotonin are thought to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)